A new report by EY projects that India’s over-the-counter (OTC) drug market is expected to nearly double by 2030, reaching INR 98,000 crore, up from around INR 47,000 crore in 2024, growing at a compound annual growth rate of about 13 per cent. The expansion is driven by rising out-of-pocket healthcare spending, increasing digital commerce, and a shift toward proactive, consumer-led wellness choices. The report highlights that self-care OTC products, including vitamins, minerals and supplements, are seeing particularly strong demand, while categories such as weight management and women’s health are also gaining traction.

Industry leaders say the market’s growth reflects changing consumer behaviour, with repeat purchases increasingly influenced by factors like product experience, brand trust and channel preferences. Analysts also caution that clearer regulatory guidelines on product classification, labelling and consumer communication are needed to support responsible self-medication and long-term investment in the OTC space.

Despite India having one of the world’s largest populations, per capita OTC spending remains significantly lower than global averages, suggesting further potential for market growth and penetration over the coming decade.